Through its research partner at the University of Queensland in Australia, PreveCeutical Medical (PRVCF, PREV) has continued moving forward with a wide-ranging drug research platform. The arrangement gives the Company exclusive license of resulting technologies and provides for royalties to UniQuest from future revenue streams when the therapeutic candidates reach commercial stage.
Recent advances demonstrate the team’s dedication and tenacity in moving forward with PreveCeutical’s research and development agenda despite lean capital resources. First, in September 2019, PreveCeutical announced additional progress in a program aimed at developing a gene therapy targeting obesity and diabetes. Second, in July 2019, PreveCeutical announced the completion of the second phase of its project to develop a nose-to-brain drug delivery system. The Company has moved on to the third and final stage to evaluate cannabinoid release from the extract-infused Sol-gel. PreveCeutical recently received permission from authorities in Queensland to use human nasal mucosal tissue in this round of tests. Third, the Company recently announced the achievement of a critical milestone in the development of non-addictive analgesics. The research team has successfully designed and synthesized lead peptide constructs that were screened for potency. The peptides were found to be on par with available pain killers such as morphine.
More details on these developments and the implications for valuation can be found in update report published October 15, 2019.
Click on the image below to access the full 10-page report.
Please note the important disclosures and disclaimers at the end of every Crystal Equity Research report.